Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?

C. Prezioso; M.A. Zingaropoli; M. Iannetta; D.M. Rodio; M. Altieri; A. Conte; V. Vullo; M.R. Ciardi; A.T. Palamara; V. Pietropaolo

doi:10.1016/j.msard.2020.102008

Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?

C. Prezioso, M.A. Zingaropoli, M. Iannetta, D.M. Rodio, M. Altieri, A. Conte, V. Vullo, M.R. Ciardi, A.T. Palamara, V. Pietropaolo

IRCCS San Raffaele Pisana

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Multiple Sclerosis and Related Disorders
Volume	41
DOIs	https://doi.org/10.1016/j.msard.2020.102008
Publication status	Published - 2020

Access to Document

10.1016/j.msard.2020.102008

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079609527&doi=10.1016%2fj.msard.2020.102008&partnerID=40&md5=b196ba7d3f2649a9057960a53ed3f92e

Cite this

Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis? / Prezioso, C.; Zingaropoli, M.A.; Iannetta, M.; Rodio, D.M.; Altieri, M.; Conte, A.; Vullo, V.; Ciardi, M.R.; Palamara, A.T.; Pietropaolo, V.

In: Multiple Sclerosis and Related Disorders, Vol. 41, 2020.

Research output: Contribution to journal › Article › peer-review

@article{bda2412919504043a8073ac904961d29,

title = "Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?",

author = "C. Prezioso and M.A. Zingaropoli and M. Iannetta and D.M. Rodio and M. Altieri and A. Conte and V. Vullo and M.R. Ciardi and A.T. Palamara and V. Pietropaolo",

note = "Cited By :1 Export Date: 29 January 2021",

year = "2020",

doi = "10.1016/j.msard.2020.102008",

language = "English",

volume = "41",

journal = "Multiple Sclerosis and Related Disorders",